Andrew W. Hahn, MD, Author at Grand Rounds in Urology

Andrew W. Hahn, MD

The University of Texas MD Anderson Cancer Center

Houston, Texas

Andrew W. Hahn, MD, is an Assistant Professor of Genitourinary Medical Oncology at the MD Anderson Cancer Center in Houston, Texas. Dr. Hahn’s research focus is to investigate how host factors influence response, resistance, and toxicity to cancer treatments and to design and run clinical trials to improve outcomes for patients with prostate and kidney cancer. His clinical focus is on prostate and kidney cancers.

Dr. Hahn earned a Bachelor of Arts in Synthetic Medicinal Chemistry and his Medical Doctorate at the University of Tennessee in Memphis. Dr. Hahn completed an internship and residency in Internal Medicine, and served as Chief Medicine Resident, at the University of Utah in Salt Lake City. Dr. Hahn then completed a fellowship in Medical Oncology at the MD Anderson Cancer Center.

Dr. Hahn has published over 50 articles and authored or co-authored 30 other editorials, reviews, and book chapters. He has been recognized for his contributions to the field, receiving numerous awards including, the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator and Career Development Awards, a Prostate Cancer Foundation Young Investigator Award, and a Department of Defense Early Investigator Research Award. Dr. Hahn is a member of the American Association for Cancer Research, American Society of Clinical Oncology, and the European Society for Medical Oncology.

Talks by Andrew W. Hahn, MD

Post-ESMO 2025 Highlights: Kidney Cancer Studies

Andrew W. Hahn, MD | Oct 2025

Dr. Andrew W. Hahn of MD Anderson Cancer Center summarizes pivotal kidney cancer studies presented at ESMO 2025, including pembrolizumab-based triplets, biomarker-guided strategies, and adjuvant immunotherapy trials, offering insight into evolving RCC treatment approaches.

Post-ESMO 2025 Highlights: Advances in Prostate Cancer Research

Andrew W. Hahn, MD | Oct 2025

At ESMO 2025, Dr. Andrew Hahn of MD Anderson Cancer Center shared updates on pivotal prostate cancer studies, including EMBARK, ENZARAD, PRESTO, and PSMA Addition, offering key survival data and next-generation therapy insights.

PET Tumor Board Case 5: A Case of a 77-year-old Prostate Cancer Patient with Ulcerative Colitis and Uncertain PET Findings

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins, MD, PhD, Sherief H. Gamie, MD, PhD, Daniel P. Petrylak, MD and Andrew W. Hahn, MD | Aug 2025

Multidisciplinary case review shows how PSMA PET false positives can mimic nodal disease and alter prostate cancer management.

PET Tumor Board – Case 4: A Case of a 66-year old Male with Elevated PSA of 9.06 and MRI Showing PI-RADS Category 4 and 5

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins, MD, PhD, Sherief H. Gamie, MD, PhD, Daniel P. Petrylak, MD and Andrew W. Hahn, MD | Aug 2025

E. David Crawford, MD, and the panel discuss a case of a 66-year-old with elevated PSA, MRI PIRADS 5 lesion, and PSA density of 0.11.

Treating Oligometastatic Prostate Cancer in the PSMA PET Era

Andrew W. Hahn, MD | May 2025

Andrew W. Hahn, MD, addresses the treatment of oligometastatic prostate cancer in the PSMA PET era from a medical oncology perspective.